Eli Lilly and Company [NYSE: LLY] stock went on an upward path that rose over 11.74% on Monday, amounting to a one-week price increase of more than 12.35%. The company report on January 11, 2021 that US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction.
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death and hospitalization for heart failure and to slow kidney function decline in adults with chronic heart failure with reduced ejection fraction, including those with and without type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.
A high unmet need remains in the treatment of heart failure, as approximately half of all those diagnosed are expected to die within five years. Heart failure is also the leading cause of hospitalization in the U.S., with an estimated one million people being hospitalized due to the condition each year. The risk of death in people with heart failure rises with each hospital admission. Heart failure with reduced ejection fraction occurs when the heart muscle does not contract effectively, and less blood is pumped out to the body compared to a normally functioning heart.
Over the last 12 months, LLY stock rose by 34.74%. The one-year Eli Lilly and Company stock forecast points to a potential downside of -5.5. The average equity rating for LLY stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $177.25 billion, with 907.20 million shares outstanding and 743.84 million shares in the current float. Compared to the average trading volume of 4.01M shares, LLY stock reached a trading volume of 11301269 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Eli Lilly and Company [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $176.24 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 10, 2020. While these analysts kept the previous recommendation, Bernstein raised their target price to Mkt Perform. The new note on the price target was released on November 10, 2020, representing the official price target for Eli Lilly and Company stock. Previously, the target price had yet another raise to $144, while Berenberg analysts kept a Hold rating on LLY stock.
The Average True Range (ATR) for Eli Lilly and Company is set at 5.21, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 7.64. The Price to Book ratio for the last quarter was 34.95, with the Price to Cash per share for the same quarter was set at 3.81. Price to Free Cash Flow for LLY in the course of the last twelve months was 63.66 with Quick ratio for the last quarter at 1.10.
LLY Stock Performance Analysis:
Eli Lilly and Company [LLY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.35. With this latest performance, LLY shares gained by 17.68% in over the last four-week period, additionally plugging by 14.72% over the last 6 months – not to mention a rise of 34.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 77.54, with the RSI for the last a single of trading hit 82.46, and the three-weeks RSI is set at 73.42 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 153.36, while it was recorded at 169.76 for the last single week of trading, and 152.78 for the last 200 days.
Insight into Eli Lilly and Company Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +25.94 and a Gross Margin at +78.85. Eli Lilly and Company’s Net Margin is presently recorded at +20.78.
Return on Total Capital for LLY is now 27.37, given the latest momentum, and Return on Invested Capital for the company is 24.17. Return on Equity for this stock inclined to 74.59, with Return on Assets sitting at 11.15. When it comes to the capital structure of this company, Eli Lilly and Company [LLY] has a Total Debt to Total Equity ratio set at 610.90. Additionally, LLY Total Debt to Total Capital is recorded at 85.93, with Total Debt to Total Assets ending up at 40.54. Long-Term Debt to Equity for the company is recorded at 548.72, with the Long-Term Debt to Total Capital now at 77.19.
Reflecting on the efficiency of the workforce at the company, Eli Lilly and Company [LLY] managed to generate an average of $137,930 per employee. Receivables Turnover for the company is 3.80 with a Total Asset Turnover recorded at a value of 0.54.Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
LLY Stock EPS
With the latest financial reports released by the company, Eli Lilly and Company posted 1.73/share EPS, while the average EPS was predicted by analysts to be reported at 1.52/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 13.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 13.66%.
Eli Lilly and Company [LLY] Insider Position Details
There are presently around $134,800 million, or 79.20% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 111,132,343, which is approximately -0.384% of the company’s market cap and around 11.70% of the total institutional ownership; VANGUARD GROUP INC, holding 69,165,364 shares of the stock with an approximate value of $12.86 billion in LLY stocks shares; and BLACKROCK INC., currently with $11.24 billion in LLY stock with ownership of nearly -3.754% of the company’s market capitalization.
Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of January and at the time of the January reporting period, where 748 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 25,648,162 shares. Additionally, 788 investors decreased positions by around 33,497,827 shares, while 331 investors held positions by with 665,819,270 shares. The mentioned changes placed institutional holdings at 724,965,259 shares, according to the latest SEC report filing. LLY stock had 132 new institutional investments in for a total of 4,364,253 shares, while 112 institutional investors sold positions of 1,761,614 shares during the same period.